A new compound called BPD-9, derived from the natural antimicrobial sanguinarine, has been shown to effectively target drug-resistant tuberculosis.
- Mycobacterium tuberculosis, which causes tuberculosis (TB), is a significant threat to public health.
- A new study identified that a semi-synthetic compound can be derived from natural compounds and shows potent activity against M. tuberculosis, including multi-drug resistant strains.
- This is a promising step toward a new potent treatment for TB.
Novel Anti-TB Compound
New research published today (October 3) in the American Society for Microbiology journal Microbiology Spectrum demonstrates that a novel semi-synthetic compound can be derived from natural compounds to produce potent activity against Mycobacterium tuberculosis, including multi-drug resistant strains. The new compound provides a promising chemical scaffold to develop new potent anti-tuberculosis drugs.
M. tuberculosis, the pathogen responsible for tuberculosis (TB), is the leading cause of bacterial disease-related death worldwide. Current antibiotic regimens for the treatment of TB are dated, require longer courses of treatment, and risk the development of drug resistance.
Innovative Antibiotic Discovery
In the new study, researchers conducted a search for novel antibiotics targeting M. tuberculosis that could also be effective against drug-resistant strains. In drug discovery, a valuable place to start looking for new antibiotics is within the world of natural compounds produced by organisms such as plants, fungi and bacteria. Sanguinarine, a natural compound with known antimicrobial properties, is extracted from an herbaceous flowering plant native to North America. Sanguinarine has been used in traditional and alternative medicine for animals, but its toxicity makes it unfit to be used as a drug in humans.
The group of researchers redesigned sanguinarine using principles of medicinal chemistry to produce a more potent antibacterial compound with reduced toxicity. In studies in test tubes and in mice, the improved version of sanguinarine, called BPD-9, was capable of killing strains of M. tuberculosis that are resistant to all front-line antibiotics used in the clinics to treat TB.
Moreover, BPD-9 was effective against non-replicating (dormant) and intracellular M. tuberculosis, which are 2 key aspects that limit the effectiveness of current anti-TB drugs. The researchers also found that BPD-9 was only active against pathogenic bacteria from the same genus as M. tuberculosis, which may spare the microbiome and other beneficial bacteria that most antibiotics harm.
Implications for Future TB Treatments
“Our findings show a new chemical entity that has unique properties in combating Mycobacterium tuberculosis, which may be harnessed further for clinical translation,” said corresponding study author Jim Sun, Ph.D., Assistant Professor in the Department of Microbiology and Immunology at The University of British Columbia.
“Our finding that the new compound is effective against other members of the Mycobacterium genus may also prove to be valuable in the fight against deadly lung infections caused by non-tuberculous mycobacteria, which are notoriously resistant to most antibiotics. It is also enticing to speculate that BPD-9 could be killing Mycobacterium tuberculosis in a way that is different than that of existing anti-TB drugs.”
Reference: “Dietary zinc supplementation inhibits bacterial plasmid conjugation in vitro by regulating plasmid replication (rep) and transfer (tra) genes” by Logan Ott, Chloe Smith and Melha Mellata, 3 October 2024, Applied and Environmental Microbiology.
DOI: 10.1128/aem.01480-24
The study was conducted in collaboration with the medicinal chemistry team of Weibo Yang, Ph.D. at the Shanghai Institute of Materia and Medica (Chinese Academy of Sciences) and bacterial genetics team of Marcel Behr, M.D., and Andréanne Lupien, Ph.D. at McGill University. The research was supported by grants from the Canadian Institutes of Health Research and the National Sanitarium Association.
Never miss a breakthrough: Join the SciTechDaily newsletter.
Follow us on Google and Google News.